Biome Australia greenlit for major probiotic trial
Biome Australia (ASX:BIO) has cleared the final regulatory hurdle to begin a landmark human clinical trial for its proprietary probiotic strain, Lactobacillus plantarum BMB18.
The La Trobe University Human Research Ethics Committee recently granted formal approval for the study, which is scheduled to commence in February.
The randomised, double-blind, placebo-controlled trial will recruit 240 participants to evaluate the strain's efficacy in managing digestive issues, sleep disturbances, and mood instability.
By utilising two active dosage levels, Biome aims to generate robust data to support the commercialisation of its wholly-owned intellectual property across its Activated Probiotics and Activated Therapeutics product lines.
At the time of reporting, Biome Australia's share price was $0.48.
More from Australia
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access
American Tungsten completes Nexus acquisition for Pinnacle MOU
Butn extends MYOB invoice financing agreement to 2027
Celsius Resources updates market on US$5M dispute
